Schedule 13D ownership disclosure

Aviragen Therapeutics Inc

Security class unavailable · CUSIP: 053761102

Event date: 2017-06-07

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
3,068,358
Percent of class
7.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-17-040227
Form type
SC 13D
Filer
Vaxart, Inc.
CIK
CIK 72444
Filed
Jun 19, 2017
Reporting period
Jun 07, 2017
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub